Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
GeneDx Holdings Corp. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights",
"One Test: Miss Less. Discover More. GeneDx"
07/24/2023 8-K Quarterly results
05/09/2023 8-K Investor presentation, Quarterly results
Docs: "GeneDx Reports First Quarter 2023 Financial Results and Business Highlights",
"One Test: Miss Less. Discover More. GeneDx"
04/28/2023 8-K Material Modifications to Rights of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appo...
Docs: "CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION",
"GENEDX HOLDINGS CORP."
04/17/2023 8-K Quarterly results
04/14/2023 8-K Quarterly results
03/14/2023 8-K Investor presentation, Quarterly results
Docs: "GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights",
"One Test: Miss Less. Discover More. GeneDx"
02/14/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/30/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "GeneDx Holdings Corp. Class A Common Stock, par value $0.0001 per share",
"FORM OF SUBSCRIPTION AGREEMENT"
01/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "41st Annual JPMorgan Healthcare Conference January 12, 2023 San Francisco One Test: Miss Less. Discover More. GeneDx"
01/09/2023 8-K Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regu...
Docs: "CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION",
"GENEDX HOLDINGS CORP.",
"Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance"
12/30/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
08/26/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDMENT NO. 1 TO",
"Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer",
"UNAUDITED COMBINED CARVE-OUT FINANCIAL STATEMENTS OF",
"UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION"
08/15/2022 8-K Investor presentation, Quarterly results
Docs: "Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results",
"2Q 2022 Earnings Presentation August 2022 Exhibit 99.2",
"Sema4 Announces Changes to its Research & Development Leadership"
07/01/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/02/2022 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "ANNEX B CERTIFICATE OF AMENDMENT",
"TRANSITION SERVICES AGREEMENT",
"AMENDED AND RESTATED EMPLOYMENT AGREEMENT",
"Consent of Independent Auditors",
"Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms",
"WAIVER AND AMENDMENT TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION",
"UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION"
04/27/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
03/14/2022 8-K Investor presentation, Quarterly results
Docs: "Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights 37% increase in fourth quarter test volumes compared to the same period last year",
"Q4 2021 Earnings Presentation March 2022 Exhibit 99.2"
03/14/2022 8-K Investor presentation, Quarterly results
Docs: "Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights 37% increase in fourth quarter test volumes compared to the same period last year",
"Q4 2021 Earnings Presentation March 2022 Exhibit 99.2"
01/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Sema4 Holdings Corp."
01/18/2022 8-K Appointed a new director
Docs: "AGREEMENT AND PLAN OF MERGER AND REORGANIZATION",
"SUBSCRIPTION AGREEMENT",
"SHAREHOLDER AGREEMENT",
"STOCKHOLDER SUPPORT AGREEMENT",
"FORM OF LOCK-UP AGREEMENT",
"Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform",
"SEQUENCE ONCE CAPTURE MAJORITY OF PATIENTS"
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "GENOMIC TESTING SOLUTIONS REVENUE SECONDARY INSIGHTS MONETIZE INFORMATION PLATFORM TO QUERY FOR INSIGHTS"
01/10/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021"
12/15/2021 8-K Other Events  Interactive Data
11/15/2021 8-K Investor presentation, Quarterly results
Docs: "Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights 36% increase in test volume compared to the same period last year",
"3,500 4,000 4,500 5,000 5,500 6,000 6,500 7,000 1/ 7/ 21 1/ 21"
10/14/2021 8-K Quarterly results
08/16/2021 8-K/A Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits  Interactive Data
Docs: "UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION",
"Mount Sinai Genomics, Inc. Condensed Balance Sheets"
08/16/2021 8-K Investor presentation, Quarterly results
Docs: "Sema4 Reports Second Quarter 2021 Financial Results and Business Highlights 85% test-volume growth compared to same period in 2020",
"1, 2020 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21"
07/28/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "Third Amended and Restated Certificate of Incorporation of Sema4 Holdings Corp",
"Restated Bylaws of Sema4 Holdings Corp",
"02/11/2021",
"Form of Director and Officer Indemnification Agreement",
"2021 Equity Incentive Award Plan",
"Form of Stock Option Agreement under the 2021 Incentive Award Plan",
"Form of RSU Agreement under the 2021 Incentive Award Plan",
"Form of Earn-Out RSU Agreement",
"2021 Employee Stock Purchase Plan",
"Amended and Restated Employment of Agreement of Eric Schadt"
07/21/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/19/2021 8-K Other Events
02/11/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among, CM Life Sciences, Inc., S-IV Sub, Inc., and Mount Sinai Genomics, Inc. d/b/a Sema4",
"Form of Subscription Agreement",
"Form of Shareholder Lock-Up Agreement",
"Sponsor Support Agreement, by and among CMLS Holdings LLC, CM Life Sciences, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4",
"Forfeiture Agreement, by and between CMLS Holdings LLC and Mount Sinai Genomics, Inc. d/b/a Sema4",
"Form of Amended and Restated Registration Rights Agreement"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy